MS 857

Drug Profile

MS 857

Alternative Names: MS-857

Latest Information Update: 31 Aug 2007

Price : $50

At a glance

  • Originator Nihon Schering
  • Class Cardiotonics; Vasodilators
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Ischaemic heart disorders

Most Recent Events

  • 20 Nov 1995 A clinical study has been added to the Heart failure pharmacodynamics section
  • 22 Sep 1995 A study has been added to the pharmacokinetics and adverse events sections
  • 22 Mar 1995 A clinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top